Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema

Sponsor
University of Sao Paulo
Study ID
NCT01487629
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab, 1.5 mg, intravitreal, throughout the study
  • Ranibizumab — DRUG
    Ranibizumab, 0.5 mg, intravitreal, throughout the study

Study Details

The purpose of this study is to compare the morphological and visual acuity outcomes associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for treatment of diabetic macular edema.

Key Dates

First listed
Dec 7, 2011
Start date
Apr 30, 2010
Status verified
Dec 2011
Primary completion
Sep 30, 2012
Completion
Sep 30, 2012

Study Design

Enrollment
53 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab
    Treatment of macular edema with intravitreal Bevacizumab
  • Experimental: Ranibizumab
    Treatment of macular edema with intravitreal Ranibizumab

Primary Outcome Measure

Central subfield macular thickness (CSFT) change [ Time Frame: Monthly from baseline to Week 48 ]

Related Studies